本帖最后由 蓝鱼o_0 于 2012-1-25 14:28 编辑
不知道您有没有看过我的点评。
您给出的第三个链接地址不正确。
以下是这篇文章的链接。
地址我 已经予以修订
The Lancet, Volume 377, Issue 9782, Pages 2023 - 2030, 11 June 2011
<Previous Article|Next Article>
doi:10.1016/S0140-6736(11)60607-7Cite or Link Using DOI
Published Online: 01 June 2011
Dexamethasone and length of hospital stay in patients with community-acquired pneumonia: a randomised, double-blind, placebo-controlled trialOriginal Text
Sabine CA Meijvis MD a , Hans Hardeman MD b, Hilde HF Remmelts MD e i, Rik Heijligenberg MD e, Ger T Rijkers PhD c, Heleen van Velzen-Blad MSc c, G Paul Voorn MD c, Ewoudt MW van de Garde PhD d f, Henrik Endeman MD g, Prof Jan C Grutters MD b h, Willem Jan W Bos MD a, Prof Douwe H Biesma MD a i
SummaryBackgroundWhether addition of corticosteroids to antibiotic treatment benefits patients with community-acquired pneumonia who are not in intensive care units is unclear. We aimed to assess effect of addition of dexamethasone on length of stay in this group, which might result in earlier resolution of pneumonia through dampening of systemic inflammation.
MethodsIn our double-blind, placebo-controlled trial, we randomly assigned adults aged 18 years or older with confirmed community-acquired pneumonia who presented to emergency departments of two teaching hospitals in the Netherlands to receive intravenous dexamethasone (5 mg once a day) or placebo for 4 days from admission. Patients were ineligible if they were immunocompromised, needed immediate transfer to an intensive-care unit, or were already receiving corticosteroids or immunosuppressive drugs. We randomly allocated patients on a one-to-one basis to treatment groups with a computerised randomisation allocation sequence in blocks of 20. The primary outcome was length of hospital stay in all enrolled patients. This study is registered with ClinicalTrials.gov, number NCT00471640.
FindingsBetween November, 2007, and September, 2010, we enrolled 304 patients and randomly allocated 153 to the placebo group and 151 to the dexamethasone group. 143 (47%) of 304 enrolled patients had pneumonia of pneumonia severity index class 4—5 (79 [52%] patients in the dexamethasone group and 64 [42%] controls). Median length of stay was 6·5 days (IQR 5·0—9·0) in the dexamethasone group compared with 7·5 days (5·3—11·5) in the placebo group (95% CI of difference in medians 0—2 days; p=0·0480). In-hospital mortality and severe adverse events were infrequent and rates did not differ between groups, although 67 (44%) of 151 patients in the dexamethasone group had hyperglycaemia compared with 35 (23%) of 153 controls (p<0·0001).
InterpretationDexamethasone can reduce length of hospital stay when added to antibiotic treatment in non-immunocompromised patients with community-acquired pneumonia.
FundingNone.
|
发表于 2012-1-24 17:34
发表于 2012-1-24 22:12
